Factors such as loss of protective estrogen after menopause or reduced ERα activity upon anti-estrogen treatment contribute to down-regulating hepatic VLDL-TG secretion; thereby, becoming a major culprit that accelerates the development of NAFLD 48. The gene discussed is ESR1; the disease is metabolic dysfunction-associated steatotic liver disease.